Oncolytics Biotech (ONCY)

Oncolytics Biotech (ONCY) Stock Price & Analysis


ONCY Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.09 - $3.39
Previous Close$2.18
Average Volume (3M)753.50K
Market Cap
Enterprise Value$140.73M
Total Cash (Recent Filing)C$24.35M
Total Debt (Recent Filing)C$479.00K
Price to Earnings (P/E)-6.7
Nov 14, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding73,368,847
10 Day Avg. Volume345,437
30 Day Avg. Volume753,495
Standard Deviation0.50
Financial Highlights & Ratios
Price to Book (P/B)9.80
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside255.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was $1.09 and its highest was $3.39 in the past 12 months.
    What is Oncolytics Biotech’s market cap?
    Currently, no data Available
    When is Oncolytics Biotech’s upcoming earnings report date?
    Oncolytics Biotech’s upcoming earnings report date is Nov 14, 2023 which is in 43 days.
      How were Oncolytics Biotech’s earnings last quarter?
      Oncolytics Biotech released its earnings results on Aug 14, 2023. The company reported -$0.088 earnings per share for the quarter, missing the consensus estimate of -$0.086 by -$0.002.
        Is Oncolytics Biotech overvalued?
        According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Oncolytics Biotech pay dividends?
          Oncolytics Biotech does not currently pay dividends.
          What is Oncolytics Biotech’s EPS estimate?
          Oncolytics Biotech’s EPS estimate is -$0.08.
            How many shares outstanding does Oncolytics Biotech have?
            Oncolytics Biotech has 72,368,800 shares outstanding.
              What happened to Oncolytics Biotech’s price movement after its last earnings report?
              Oncolytics Biotech reported an EPS of -$0.088 in its last earnings report, missing expectations of -$0.086. Following the earnings report the stock price went up 0.985%.
                Which hedge fund is a major shareholder of Oncolytics Biotech?
                Currently, no hedge funds are holding shares in ONCY


                Oncolytics Biotech Stock Smart Score

                The Oncolytics Biotech stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Oncolytics Biotech

                Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Moleculin Biotech
                Vascular Biogenics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis